Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide in high-risk non-metastatic castration-resistant prostate cancer
2013-003820-36Phase 3Completed
- Sponsor
- Bayer
- Start
- Jun 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Darolutamide arm with Placebo arm (2 arms). Primary endpoint: Metastasis-free survival. Started Jun 2014; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2013-003820-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003820-36.